Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Migraine

  Free Subscription


Articles published in Rev Neurol

Retrieve available abstracts of 16 articles:
HTML format



Single Articles


    June 2021
  1. LAINEZ-ANDRES JM, Ashina M, Belvis R, Diaz-Insa S, et al
    1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress.
    Rev Neurol. 2021;72.
    PubMed     Abstract available


  2. MARIN-GRACIA M, Hernando-Quintana N, Lopez-Bravo A, Garcia-Arguedas C, et al
    [Degree of compliance with treatment at three months in migraine patients].
    Rev Neurol. 2021;72:377-383.
    PubMed     Abstract available


    February 2021
  3. MARTINEZ-PIAS E, Garcia-Azorin D, Trigo-Lopez J, Sierra A, et al
    [Chronic migraine with daily headache. Literature review].
    Rev Neurol. 2021;72:133-140.
    PubMed     Abstract available


    December 2020
  4. PLANCHUELO-GOMEZ A, Garcia-Azorin D, Guerrero-Peral AL, Aja-Fernandez S, et al
    [Response prediction for chronic migraine preventive treatment by gray matter morphometry in magnetic resonance imaging: a pilot study].
    Rev Neurol. 2020;71:399-406.
    PubMed     Abstract available


    August 2020
  5. NAVARRO-PEREZ MP, Marin-Gracia M, Bellosta-Diago E, Santos-Lasaosa S, et al
    [Epidemiology of migraine in Spain and Latin America].
    Rev Neurol. 2020;71:110-118.
    PubMed     Abstract available


    June 2020
  6. MAYA-CASALPRIM G, Rudilosso S, Serrano E, Reyes-Leiva D, et al
    [Late-onset migraine equivalent with prolonged aura and altered brain perfusion].
    Rev Neurol. 2020;70:430-432.
    PubMed    


    May 2020
  7. LARROSA-CAMPO D, Meilan-Martinez A, Ramon-Carbajo C, Santamarta-Liebana E, et al
    [Is there a relationship between white matter lesions associated with migraine and patent foramen ovale? Analysis of a series of patients with chronic migraine].
    Rev Neurol. 2020;70:372-378.
    PubMed     Abstract available


    April 2020
  8. BARRAL E, Buonanotte F
    [Pain catastrophizing and medication overuse in patients with chronic migraine].
    Rev Neurol. 2020;70:282-286.
    PubMed     Abstract available


    February 2020
  9. DOCTOROVICH ED, Martin-Bertuzzi F, Goicochea MT, Miranda S, et al
    [Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine].
    Rev Neurol. 2020;70:149-158.
    PubMed     Abstract available


    September 2018
  10. DE LERA M, Lopez-Mesonero L, Pedraza MI, Martinez-Velasco E, et al
    [Nasal congestion as an autonomic symptom accompanying migraine attacks].
    Rev Neurol. 2018;67:193-194.
    PubMed    


    August 2017
  11. GARCIA-ESTEVEZ DA, Pardo-Parrado M, Silvarrey-Rodriguez S
    [Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
    Rev Neurol. 2017;65:153-156.
    PubMed     Abstract available


    April 2017
  12. ALCANTARA-MONTERO A, Sanchez-Carnerero CI
    [Treatment of migraine in adults in the emergency department: recommendations of the American Headache Society].
    Rev Neurol. 2017;64:382-383.
    PubMed    


    January 2017
  13. MARTINEZ E, Ruiz-Pinero M, de Lera M, Baron J, et al
    [Clinical characteristics of vestibular migraine: considerations in a series of 41 patients].
    Rev Neurol. 2017;64:1-6.
    PubMed     Abstract available


    November 2016
  14. RAMOS-ROMERO ML, Sobrino-Mejia FE
    [Calcitonin gene-related peptide: a key player neuropeptide in migraine].
    Rev Neurol. 2016;63:460-468.
    PubMed     Abstract available


    October 2016
  15. ALVARO-GONZALEZ LC
    [Migraine and evolutionary theory: paths for a clinical approach].
    Rev Neurol. 2016;63:315-25.
    PubMed     Abstract available


    March 2016
  16. LIEBANA S
    [Alice in Wonderland syndrome as a prodrome of streptococcal tonsillopharyngitis].
    Rev Neurol. 2016;62:284-6.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: